


Active Filter(s):
Details:
Renazorb (Lanthanum Dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. it is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Lead Product(s): Lanthanum Carbonate
Therapeutic Area: Nephrology Product Name: Renazorb
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2022
Details:
Under the terms of the asset purchase agreement, Unicycive has acquired global rights for Renazorb and all its trademark and associated patents, and Spectrum has received an equity interest in Unicycive along with milestone and royalty payments.
Lead Product(s): Lanthanum Carbonate
Therapeutic Area: Nephrology Product Name: Renazorb
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Unicycive Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 14, 2020